Evidence map›Paper›PMID 29368272›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2018

Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.

Yu-Jie Dai, Yi-Bo Qiu, Rong Jiang, Man Xu, Ling-Yao Liao, George G Chen, Zhi-Min Liu

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Molecular Chaperones and Thyroid Cancer.International journal of molecular sciences · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yu-Jie DaiDepartment of Biochemistry and Molecular Biology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China.
Yi-Bo QiuDepartment of Biochemistry and Molecular Biology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China.
Rong JiangDepartment of Pathology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing, China.
Man XuDepartment of Pathology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing, China.
Ling-Yao LiaoDepartment of Biochemistry and Molecular Biology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China.
George G ChenDepartment of Surgery, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T, Hong Kong, China.
Zhi-Min LiuDepartment of Biochemistry and Molecular Biology, Molecular Medicine and Cancer Research Center, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing, 400016, China. liuzm9999@163.com.
Chongqing Medical University · CNChinese University of Hong Kong · CN

Funding

National Natural Science Foundation of China 81272937
6 · The paper itself

Abstract

purposePapillary thyroid cancer (PTC) is more common in women than in men. It has been suggested that estrogen may be involved in its development, as has previously been shown for breast, endometrial and ovarian cancer. The purpose of this study was to assess correlations between the expression of the estrogen receptor alpha36 (ERα36) and the glucose regulated proteins GRP78 and GRP94 (chaperones involved in glycoprotein folding) and various PTC clinicopathological features, as well as to evaluate the potential usefulness of these three potential oncogenic proteins in the prediction of aggressive PTC behavior.

methodsERα36, GRP78 and GRP94 protein expression in 218 primary PTC tissues and PTC-derived BCPAP cells was examined using immunohistochemistry, Western blotting and immunocytochemistry. The proliferative, invasive and migrative capacities of BCPAP cells in which the respective genes were either exogenously over-expressed or silenced were assessed using BrdU incorporation and Transwell assays, respectively.

resultsWe found that ERα36, GRP78 and GRP94 protein expression was upregulated in the primary PTC tissues tested. We also found that ERα36, GRP78 and GRP94 expression modulation affected the proliferation, invasion and migration of PTC-derived BCPAP cells. A positive correlation and a positive feedback loop were noted between ERα36, GRP78 and GRP94 protein expression in the primary PTC tissues and in BCPAP cells, respectively. High ERα36 expression in combination with a high GRP78/ GRP94 expression was found to have a stronger correlation with extrathyroid extension (ETE), lymph node metastasis (LNM), distant metastasis (DM) and high TNM stage than high ERα36 expression in combination with either high GRP78 or high GRP94 expression (p = 0.028 for ETE, p = 0.002 for DM and p ≤ 0.001 for LNM and high TNM stage) or high ERα36 expression alone (p < 0.001 for ETE, LNM, DM and high TNM stage).

conclusionsFrom our data we conclude that a concomitant high expression of ERα36, GRP78 and GRP94 is strongly associated with aggressive PTC behavior and may be used as a predictor for ETE, LNM, DM and high TNM stage.

Indexed as

AdultCarcinoma, PapillaryCohort StudiesEndoplasmic Reticulum Chaperone BiPEstradiolEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHeat-Shock ProteinsHSP70 Heat-Shock ProteinsHumansMaleMembrane GlycoproteinsMembrane ProteinsMiddle AgedThyroid Cancer, PapillaryEndoplasmic Reticulum Chaperone BiPendoplasminEstradiolEstrogen Receptor alphaestrogen receptor alpha 36, humanglucose-regulated proteinsHeat-Shock ProteinsHSP70 Heat-Shock ProteinsHSPA5 protein, humanMembrane GlycoproteinsMembrane ProteinsERα36GRP78GRP94Papillary thyroid cancer

Identifiers

PMID29368272
PMCPMC12995223
OpenAlexW2792502570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.